Difference between revisions of "TFE3"
Jump to navigation
Jump to search
m (other tumours) |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 16: | Line 16: | ||
}} | }} | ||
'''TFE3''' is an [[immunostain]] used in [[uropathology]] and [[soft tissue pathology]]. | '''TFE3''' is an [[immunostain]] used in [[uropathology]] and [[soft tissue pathology]]. | ||
The reliability of the immunostain for detecting TFE3 rearrangments has been questioned by at least one study.<ref name=pmid30851332>{{cite journal |vauthors=Sharain RF, Gown AM, Greipp PT, Folpe AL |title=Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study |journal=Hum Pathol |volume=87 |issue= |pages=65–74 |date=May 2019 |pmid=30851332 |doi=10.1016/j.humpath.2019.02.008 |url=}}</ref> | |||
==Negative== | ==Negative== | ||
| Line 25: | Line 27: | ||
*[[Alveolar soft part sarcoma]]. | *[[Alveolar soft part sarcoma]]. | ||
* YAP-TFE3 translocated [[epithelioid hemangioendothelioma]] | * YAP-TFE3 translocated [[epithelioid hemangioendothelioma]] | ||
*[[Epithelioid angiomyolipoma]] | *[[Epithelioid angiomyolipoma]]. | ||
*[[Granular cell | *[[Granular cell tumour]].<ref>{{cite journal |authors=Chamberlain BK, McClain CM, Gonzalez RS, Coffin CM, Cates JM |title=Alveolar soft part sarcoma and granular cell tumor: an immunohistochemical comparison study |journal=Hum. Pathol. |volume=45 |issue=5 |pages=1039–44 |date=May 2014 |pmid=24746209 |doi=10.1016/j.humpath.2013.12.021 |url=}}</ref> | ||
==See also== | ==See also== | ||
Latest revision as of 03:49, 16 October 2023
| TFE3 | |
|---|---|
| Immunostain in short | |
| Use | screen to detect TFE3 rearrangements |
| Subspeciality | urologic pathology, soft tissue pathology |
| Normal staining pattern | nuclear stain |
| Positive | Xp11.2 translocation carcinoma, alveolar soft part sarcoma |
| Negative | normal tissues |
TFE3 is an immunostain used in uropathology and soft tissue pathology.
The reliability of the immunostain for detecting TFE3 rearrangments has been questioned by at least one study.[1]
Negative
- Normal tissue.[2]
- Staining in normal tissue described as "extremely rare" - negative in adrenal gland, breast, colon, gallbaldder, lymph node, liver, prostate and skin.[3]
Positive
- Xp11.2 translocation carcinoma.
- Alveolar soft part sarcoma.
- YAP-TFE3 translocated epithelioid hemangioendothelioma
- Epithelioid angiomyolipoma.
- Granular cell tumour.[4]
See also
References
- ↑ "Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study". Hum Pathol 87: 65–74. May 2019. doi:10.1016/j.humpath.2019.02.008. PMID 30851332.
- ↑ URL: http://www.ihcworld.com/_newsletter/2003/focus_jul_2003.pdf. Accessed on: September 11, 2017.
- ↑ Argani, P.; Lal, P.; Hutchinson, B.; Lui, MY.; Reuter, VE.; Ladanyi, M. (Jun 2003). "Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.". Am J Surg Pathol 27 (6): 750-61. PMID 12766578.
- ↑ Chamberlain BK, McClain CM, Gonzalez RS, Coffin CM, Cates JM (May 2014). "Alveolar soft part sarcoma and granular cell tumor: an immunohistochemical comparison study". Hum. Pathol. 45 (5): 1039–44. doi:10.1016/j.humpath.2013.12.021. PMID 24746209.